Phase II trial of capecitabine (Xeloda) + nab-paclitaxel (Abraxane) in patients with metastatic pancreatic cancer
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Capecitabine (Primary) ; Capecitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Mar 2022 Status changed from active, no longer recruiting to completed.
- 12 Aug 2013 New trial record